e-Drug3D

2008

RISDIPLAM

INN
RISDIPLAM

cas 1825352-65-5

CLASS

MUSCULO-SKELETAL
TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA)
A SURVIVAL OF MOTOR NEURON 2 (SMN2)-DIRECTED RNA SPLICING MODIFIER

ROUTE (list)

ORAL

ATC code

M09AX10

PK parameters

Tmax 2.5 HOUR
VD 409.5 LITER (65 KILOGRAM)
Cl 2.1 LITER / HOUR
PPB 11 PERCENT
t1/2 50 HOUR

Target

TARGET MRNA

DrugCentral

Unknown

Download SDF file

4H-Pyrido[1,2-a]pyrimidin-4-one, 7-(4,7-diazaspiro[2.5]oct-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-

Formula:
C22H23N7O

Calculated chemical properties:

MW 401.47
NB_atoms 30
XLogP 1.96
PSA 74.981
NB_HD 1
NB_HA 8
fsp3 0.36
Lipinski(0=no;1=yes) 1

FDA
NDA 213535 (label) INN (RISDIPLAM) EVRYSDI (GENENTECH INC) APPROVAL= AP YEAR= 2020 NEWMOLECULARENTITY
NDA 219285 (label) INN (RISDIPLAM) EVRYSDI (GENENTECH INC) APPROVAL= AP YEAR= 2025